You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Oncopeptides, Investor call, 2024
Sector: Health care - Pharmaceuticals & Biotechnology
Activity: Pressconference
Language: English
Oncopeptides hereby announces that the Board of Directors has decided to carry out a fully guaranteed new share issue of approximately SEK 300 million with preferential rights for the Company’s existing ordinary shareholders (the “Rights Issue”), subject to approval by an extraordinary general meeting which is planned to be held on 15 April 2024. The purpose of the Rights Issue is primarily to finance the ongoing commercialization of Pepaxti® in Europe until the Company expects to become cash flow positive by the end of 2026.
For more information click here.